Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

Figure 2 from A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2

<p>Exposure-time profile of SDX-7320 and SDX-7539 in cycle 1 (<i>n</i> = 5) in patients dosed at 49 mg/m<sup>2</sup> SDX-7320. Plasma samples were prepared from blood drawn at the indicated times postdose. The levels of SDX-7320 and the small molecule SDX-7539 were meas...

詳細記述

保存先:
書誌詳細
第一著者: Monica M. Mita (21585118) (author)
その他の著者: Alain C. Mita (21585121) (author), Bradley J. Carver (18491067) (author), James M. Shanahan (18491064) (author), Benjamin A. Mayes (18491052) (author), Pierre J. Dufour (18491061) (author), David Browning (21585124) (author), Alfred Anderson-Villaluz (21585127) (author), John S. Petersen (18491055) (author), David J. Turnquist (18491058) (author), Peter Cornelius (18491049) (author)
出版事項: 2025
主題:
Cancer
Cancer Detection and Diagnosis
Therapeutic Research and Development
Clinical Research and Trials
Biomarkers
Protein biomarkers
Pharmacology
Pharmacokinetics and pharmacodynamics
Phase I Clinical Trials
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
その他の書誌記述
要約:<p>Exposure-time profile of SDX-7320 and SDX-7539 in cycle 1 (<i>n</i> = 5) in patients dosed at 49 mg/m<sup>2</sup> SDX-7320. Plasma samples were prepared from blood drawn at the indicated times postdose. The levels of SDX-7320 and the small molecule SDX-7539 were measured by LC/MS-MS.</p>

類似資料